Leukemia and Lymphoma

If it's true that a picture is worth a thousand words, the same can be said for numbers.  For any healthcare executive, a look at relevant statistics can be revealing. Here are some of the top stats to know.

When it comes to promising areas in the treatment of lymphoma and other blood cancers, gene therapy may be at the top of the list. Here’s why.

Two oncology practices have wish list items for payers. Find out what they are.

In this era of precision oncology and targeted therapies for cancer, it’s even more important to include different populations when doing clinical trials. Here are three effective strategies.

Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society, offers a quick overview of current developments as well as a look forward.

What does team-based cancer care done right look like? Here are two real-word models worth emulating.

A new study investigates whether PET scans can help guide treatment in patients with aggressive non-Hodgkin lymphomas.

As a healthcare executive you may not conduct research or administer medications, but you can still play an important role in helping improve treatment for lymphoma as well as other blood cancers.  Here are five areas in which you can make an impact.

A lymphoma expert from the Allegheny Health Network Cancer Institute reveals the status of current and pipeline lymphoma treatments and the three new treatments healthcare executives need to keep on their radar.

New Cardinal Health Specialty Solutions research shares inside information about oncologists’ views about targeted therapies.

University of Pennsylvania researchers share evidence-based strategies for reducing unplanned emergency department and hospitalizations of patients with cancer.

A study evaluated how treating military veterans with HCV early impacted their risk for non-Hodgkin lymphoma and various other diseases.

Treating patients with cancer is often challenging yet rewarding work. But caring for patients in an urban setting, where some patients don’t speak English and other patients aren’t fully insured and possibly facing significant financial challenges.

Can you identify the latest developments related to the treatment of blood cancers? Test your knowledge.

Montefiore Medical Center in Bronx, New York, is participating in CMS’ oncology care model, a value-based payment arrangement. Find out what new group of staff members is helping it succeed.

Analysis from Avalere shows why healthcare execs should understand how oncology practices are evolving in response to the OCM.

In a decision reached through the joint FDA/CMS Parallel Review process, CMS has granted national Medicare coverage to next-generation sequencing tests approved or cleared by the FDA as companion diagnostics for cancer therapies. This is clearly a win for Medicare beneficiaries and some NGS test providers-but is it also good news for MCOs?

Two experts highlight noteworthy updates in the transplant and cellular therapy space. Read more.

New treatment approaches could lead to even higher costs associated with lymphoma. However, experts say these treatments hold great promise and could reduce costs in the long-term.

Unique trends are occurring in the pharmaceutical pipeline that would have been unheard of just five years ago.

Ron Barkley, president of the Cancer Center Business Development Group, which consults with oncology providers on value-based care arrangements, shares tips.

Technology professionals shed light on the “Wearable Revolution,” what’s new in wearables, and what the future holds.

The current state of precision medicine and how it could soon help doctors predict diseases before the onset of symptoms.

CEO of a Pennsylvania-based oncology group shares how participating in a new value-based model is changing the care approach.